Health Technology Assessment Under Scrutiny - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Health Technology Assessment Under Scrutiny
The rising cost of healthcare has complicated the introduction of new, innovative drugs and other medical technologies. While the medical impact of these healthcare advances cannot be denied, governments and healthcare policy makers have found it difficult to sustain the funding of these expensive treatments.


Pharmaceutical Technology Europe
Volume 23, Issue 9

References

1. C.S Goodman, "HTA 101: Introduction to Health Technology Assessment" (National Information Center on Health Services Research and Healthcare Technology, US National Library of Medicine, National Institutes of Health, January, 2004), http://www.nlm.nih.gov/, accessed 12 August 2011.

2. H. Redwood, Why Ration Health Care? (CIVITAS, London, UK 2000).

3. Charles River Associates, A Comparative Analysis Of The Role And Impact Of Health Technology Assessment (2011, MA, USA).

4. C. Sorenson, M. Drummond and P. Kanavos, The Role Of Health Technology Assessment In The European Union. The European Observatory on Health Systems and Policies (MPG Books, Cornwall, UK, 2008).

5. Tufts Center for the Study of Drug Development, "Drug Developers Are Aggressively Changing the Way They Do R&D", Press Release (MA, USA, 2011).

6. K. Grogan, "Uproar over NICE rejection of Novartis MS pill", Pharma Times (5 August 2011).

7. International Society for Pharmacoeconomics and Outcomes Research (ISPOR), "The German IQWiG — It's Not NICE Benefit Assessment in Germany — New Sense or Nuisance?" http://www.ispor.org/, accessed 8 August 2011.

8. International Network of Agencies for Health Technology Assessment (INAHTA), "IQWIG — Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen" http://www.inahta.org/, accessed 8 August 2011.

9. A. Jouan, Le Figaro (27 March 2011). http://www.lefigaro.fr/, accessed 12 August 2011.

10. Haute Autorité de Santé, "Le NICE, l'IQWIG et la HAS concluent un accord de coopération", Press Release, (France, 13 April 2006).

11. Haute Autorité de Santé, "Mise au point de la Haute Autorité de Santé sur Mediator", Press Release, (France, 1 December 2010).

12. A. Braillon, The Lancet, 377 (9782), 2003–2004 (2011).

13. EFPIA, "New Study on HTA Processes Highlights Areas for Improvement to Accelerate Patients' Access to Innovative Medicines", Press Release (Belgium, 13 July 2011).London, UK


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology Europe,
Click here